Skip Therapeutics Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
4
- Latest Deal Type
-
Seed
- Investors
-
10
Skip Therapeutics General Information
Description
Developer of RNA-based precision treatments intended to identify patient cohorts and determine therapeutic designs. The company's treatments use splice-modulating antisense oligonucleotides (ASOs) for analyzing mutation data at scale, enabling medical practitioners to identify treatable patient cohorts optimize target selection, and recognize available molecular strategies to restore protein function.
Contact Information
Website
www.skiptx.comCorporate Office
- 2 Ilan Ramon Street
- Ness Ziona 7403635
- Israel
Corporate Office
- 2 Ilan Ramon Street
- Ness Ziona 7403635
- Israel
Skip Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 1. Seed Round | 01-May-2021 | Completed | Generating Revenue |
Skip Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Skip Therapeutics Patents
Skip Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2025238644-A1 | Compositions and methods for treating retinal diseases | Pending | 16-May-2024 | ||
| EP-4619047-A1 | Compositions and methods for treating retinal diseases | Pending | 17-Nov-2022 | ||
| US-20250283093-A1 | Compositions and methods for treating retinal diseases | Pending | 17-Nov-2022 | ||
| WO-2024105673-A1 | Compositions and methods for treating retinal diseases | Inactive | 17-Nov-2022 | ||
| EP-4551231-A1 | Compositions and methods for treating primary ciliary dyskinesia | Pending | 07-Jul-2022 | A61P11/00 |
Skip Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Skip Therapeutics Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Angel (individual) | Minority | |||
| FutuRx | Accelerator/Incubator | Minority | ||
| Innovation Authority | Government | Minority | ||
| Johnson & Johnson JJDC | Corporate Venture Capital | Minority | ||
| Leaps by Bayer | Corporate Venture Capital | Minority |
Skip Therapeutics FAQs
-
When was Skip Therapeutics founded?
Skip Therapeutics was founded in 2021.
-
Where is Skip Therapeutics headquartered?
Skip Therapeutics is headquartered in Ness Ziona, Israel.
-
What is the size of Skip Therapeutics?
Skip Therapeutics has 4 total employees.
-
What industry is Skip Therapeutics in?
Skip Therapeutics’s primary industry is Drug Discovery.
-
Is Skip Therapeutics a private or public company?
Skip Therapeutics is a Private company.
-
What is Skip Therapeutics’s current revenue?
The current revenue for Skip Therapeutics is .
-
Who are Skip Therapeutics’s investors?
, FutuRx, Innovation Authority, Johnson & Johnson JJDC, and Leaps by Bayer are 5 of 10 investors who have invested in Skip Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
